Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 9
Submit an article Journal homepage
273
Views
11
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study

Owen A. O’ConnorCenter for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, USACorrespondence[email protected]
,
John GerecitanoMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Henrik Van DeventerUNC Linenberger Cancer Center, Chapel Hill, NC, USA
,
John HainsworthSarah Cannon Research Institute, Nashville, TN, USA
,
Kelly M. ZulloCenter for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, USA
,
Khalil SaikaliCytokinetics, Inc., South San Francisco, CA, USA
,
Joseph SeroogyCytokinetics, Inc., South San Francisco, CA, USA
,
Andrew WolffCytokinetics, Inc., South San Francisco, CA, USA
&
Rafael EscandónCytokinetics, Inc., South San Francisco, CA, USA
 show all
Pages 2585-2591 | Received 03 Sep 2014, Accepted 29 Dec 2014, Published online: 10 Feb 2015

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Esperanza Macarena Algarín, Susana Hernández-García, Mercedes Garayoa & Enrique M. Ocio. (2020) Filanesib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 29:1, pages 5-14.
Read now
Danielle Bongero, Luca Paoluzzi, Enrica Marchi, Kelly M. Zullo, Roberto Neisa, Yinghui Mao, Rafael Escandon, Ken Wood & Owen A. O’Connor. (2015) The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma. Leukemia & Lymphoma 56:10, pages 2945-2952.
Read now

Articles from other publishers (9)

Anna C. Impastato, Andrej Shemet, Nynke A. Vepřek, Gadiel Saper, Henry Hess, Lu Rao, Arne Gennerich & Dirk Trauner. (2022) Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor. Angewandte Chemie International Edition 61:9.
Crossref
Anna C. Impastato, Andrej Shemet, Nynke A. Vepřek, Gadiel Saper, Henry Hess, Lu Rao, Arne Gennerich & Dirk Trauner. (2022) Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor. Angewandte Chemie 134:9.
Crossref
Alfonso Serrano-del Valle, Chantal Reina-Ortiz, Andrea Benedi, Alberto Anel, Javier Naval & Isabel Marzo. (2021) Future prospects for mitosis-targeted antitumor therapies. Biochemical Pharmacology 190, pages 114655.
Crossref
Pedro Novais, Patrícia M. A. Silva, Isabel Amorim & Hassan Bousbaa. (2021) Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics 13:7, pages 1011.
Crossref
Gerhard Jungwirth, Tao Yu, Junguo Cao, Montadar Alaa Eddine, Mahmoud Moustafa, Rolf Warta, Juergen Debus, Andreas Unterberg, Amir Abdollahi & Christel Herold-Mende. (2021) KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Letters 506, pages 1-10.
Crossref
Isabel Garcia-Saez & Dimitrios A. Skoufias. (2021) Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. Biochemical Pharmacology 184, pages 114364.
Crossref
Tian-Fu Li, Hui-Juan Zeng, Zhen Shan, Run-Yi Ye, Tuck-Yun Cheang, Yun-Jian Zhang, Si-Hong Lu, Qi Zhang, Nan Shao & Ying Lin. (2020) Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer. Cancer Cell International 20:1.
Crossref
Jungwirth, Yu, Moustafa, Rapp, Warta, Jungk, Sahm, Dettling, Zweckberger, Lamszus, Senft, Loehr, Keßler, Ketter, Westphal, Debus, von Deimling, Simon, Unterberg, Abdollahi & Herold-Mende. (2019) Identification of KIF11 As a Novel Target in Meningioma. Cancers 11:4, pages 545.
Crossref
Xinran Liu, Yuchen Chen, Yangkai Li, Robert B. Petersen & Kun Huang. (2019) Targeting mitosis exit: A brake for cancer cell proliferation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:1, pages 179-191.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.